Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

89.51 +0.69 (+0.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
51 52 Next >
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
From Gilead Sciences, Inc.
Via Business Wire
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
It helps to offer products everyone needs. 
Via The Motley Fool
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Price Over Earnings Overview: Gilead Sciences
Via Benzinga
This Is What Whales Are Betting On Gilead Sciences
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
Read the latest report on NanoViricides here. 
Via Benzinga
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
These stocks are built to withstand a bear market. 
Via The Motley Fool
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences' Debt Overview
Via Benzinga
Ominous Death Cross Forms On Gilead Sciences's Chart
Via Benzinga
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,  
Via Benzinga
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
From Gilead Sciences, Inc.
Via Business Wire
7 Tech Stocks to Watch on July 14
Tech stocks are on the rise today ahead of the upcoming Nasdaq 100 rebalancing, the changes for which will be announced this Friday, July 14. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Nasdaq 100 Index Shake-Up Rattles High-Flying Stocks of 2023
The Nasdaq 100 index is set for a special rebalancing. Seven mega-cap stocks driving the market's gains, as well as other stocks, face weighting adjustments. 
Via MarketBeat
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Read the latest report on NanoViricides here. 
Via Benzinga
Is Johnson & Johnson Stock a Buy Now?
Some businesses never go out of style. 
Via The Motley Fool
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
Exposures COVID-19 Economy
The 3 Best Biotech Stocks to Buy In July
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Read the latest report on NanoViricides here. 
Via Benzinga
Inflammatory Bowel Disease Market expected to rise | Companies – Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
Via AB Newswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Inc. Dividend Stock Analysis
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
51 52 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.